BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Approves Cefepime for Use In B.Braun Medical's DUPLEX(R) System


5/11/2010 10:01:52 AM

BETHLEHEM, Pa., May 11 /PRNewswire/ -- The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Used in hospitals and healthcare centers to treat a wide variety of bacterial infections, Cefepime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. The availability of 1g and 2g Cefepime in the DUPLEX® System will mean faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.

"Making 1g and 2g Cefepime available to healthcare workers in B. Braun's DUPLEX® Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy," said Rob Albert, Vice President of Marketing for B. Braun Medical Inc.

The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.

Healthcare workers administering 1g or 2g Cefepime through DUPLEX® simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Customers interested in obtaining more information can call: 1-888-422-7286 (1-888-4BBRAUN).

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

SOURCE B. Braun Medical Inc.



Read at BioSpace.com

   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES